Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis

This study aimed to compare the effects of abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT) with those of combined androgen blockade (CAB) therapy in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). This study retrospectively identified 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumura, Naoki, Fujita, Kazutoshi, Nishimoto, Mitsuhisa, Yamamoto, Yutaka, Kuwahara, Ken, Nagai, Yasuharu, Minami, Takafumi, Hatanaka, Yuji, Nozawa, Masahiro, Morimoto, Yasuhiro, Tahara, Hideo, Uejima, Shigeya, Esa, Atsunobu, Hirayama, Akihide, Yoshimura, Kazuhiro, Uemura, Hirotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724311/
https://www.ncbi.nlm.nih.gov/pubmed/34993133
http://dx.doi.org/10.3389/fonc.2021.769068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724311/
https://www.ncbi.nlm.nih.gov/pubmed/34993133
http://dx.doi.org/10.3389/fonc.2021.769068

Ejemplares similares